Differential effects of cladribine and gemcitabine on erythroid and granulocytic progenitors from patients with chronic myeloid leukemia

Leuk Res. 1999 Dec;23(12):1121-6. doi: 10.1016/s0145-2126(99)00142-3.

Abstract

Chronic myeloid leukemia (CML) is a clonal neoplastic disease that originates in a pluripotent stem cell. Selection of normal progenitors by graft-purging may improve the outcome after autologous transplantation. In our methylcellulose assays, the nucleoside analogs cladribine (2-CdA) and gemcitabine (dFdC) showed more prominent inhibitory effects on CML than normal bone marrow (BM) progenitors. For dFdC, however, long-term incubations were necessary to achieve complete inhibition. Deoxycytidine kinase, the key enzyme of both 2-CdA and dFdC metabolisms, was only partially responsible for this differential sensitivity. We suggest that 2-CdA and dFdC might be helpful in purging of CML BM cells before autologous BM transplantation. Further studies on more primitive cells are warranted.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimetabolites, Antineoplastic / pharmacology*
  • Bone Marrow Cells / drug effects
  • Bone Marrow Purging / methods*
  • Cells, Cultured / drug effects
  • Cladribine / pharmacology*
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / pharmacology
  • Deoxycytidine Kinase / metabolism
  • Gemcitabine
  • Hematopoietic Stem Cells / drug effects
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Neoplastic Stem Cells / drug effects

Substances

  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Cladribine
  • Deoxycytidine Kinase
  • Gemcitabine